clinical trial · NCT05130567
A Study of LP-128 Capsules in Healthy Subjects
Guangzhou Lupeng Pharmaceutical Company LTD.·phase1·active not recruiting·n = 104
Chronic Hepatitis bLP-128 capsulesMatching Placebo
brief summary
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects
started
Nov 19, 2021
primary completion
Sep 30, 2026
completion
Dec 30, 2026
last updated
Apr 3, 2025
detailed description
This trial includes single dose and multiple dose phases. The single-dose phase included six dose cohorts. Based on the safety and pharmacokinetic results of single-dose study, approximately 2 doses will be selected to conduct multiple-dose study. The primary study objectives are to evaluate the safety, tolerability, and pharmacokinetic characteristics of LP-128 capsules in healthy subjects after single and multiple dosing.
official title
A Randomized Study of LP-128 Capsules vs. Placebo to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol